Report: GSK has no plans to sell HIV unit
Report: GSK has no plans to sell HIV unit Fierce Biotech
View ArticleGlaxo-Pfizer AIDS Pill May Dislodge Bristol’s, Study Suggests
Glaxo-Pfizer AIDS Pill May Dislodge Bristol’s, Study Suggests Bloomberg
View ArticleGlaxo Is ‘Happy’ With Human Genome Relationship, Viiv Venture
Glaxo Is ‘Happy’ With Human Genome Relationship, Viiv Venture Bloomberg
View ArticleCan These 3 Companies Take Down Gilead?
Can These 3 Companies Take Down Gilead? Motley Fool
View ArticleShionogi applies for HIV drug approval in U.S., Europe
Shionogi applies for HIV drug approval in U.S., Europe Reuters
View ArticleGlaxo Says No Plan for Viiv Spinoff ‘at the Moment’
Glaxo Says No Plan for Viiv Spinoff ‘at the Moment’ Bloomberg
View ArticleGSK wins priority status for new HIV drug in U.S.
GSK wins priority status for new HIV drug in U.S. Reuters
View ArticleGlaxo’s, Pfizer’s ViiV Licenses HIV Drug for Kids to Patent Pool
Glaxo’s, Pfizer’s ViiV Licenses HIV Drug for Kids to Patent Pool Bloomberg
View ArticleViiV Healthcare Partnership Anticipates New HIV Treatment Approval
ViiV Healthcare Partnership Anticipates New HIV Treatment Approval Seeking Alpha
View ArticleGlaxo Wins U.S. FDA Approval for New Daily HIV Therapy
Glaxo Wins U.S. FDA Approval for New Daily HIV Therapy Bloomberg
View ArticleFDA Delivers a Double Dose of Good News in the Fight Against HIV
FDA Delivers a Double Dose of Good News in the Fight Against HIV Motley Fool
View ArticleCan This HIV Drug Challenge Gilead's Domination?
Can This HIV Drug Challenge Gilead's Domination? Motley Fool
View ArticleViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of...
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1 Yahoo
View ArticleViiV Healthcare files new drug application for three-drug HIV pill with US FDA
ViiV Healthcare files new drug application for three-drug HIV pill with US FDA Pharmaceutical-Technology
View Article
